Supplier log in
Future Procurement Opportunity (FPO) – Supply of various vaccines and seasonal influenza vaccine
Details
| RFx ID : | 31239774 |
| Tender Name : | Future Procurement Opportunity (FPO) – Supply of various vaccines and seasonal influenza vaccine |
| Reference # : | A1888672 |
| Open Date : | Q1 2025 |
| Indicative RFx Release Date : | Q2 2025 [?] |
| Tender Type : | Future Procurement Opportunity (FPO) |
| Project Status : | Initial development [?] |
| Indicative Total Value : | $50M - $100M [?] |
| Expected number of contracts offered : | 6 |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team procurement@Pharmac.govt.nz |
Pharmac is planning on issuing a Request for Proposals (RFP) for supply of various vaccines and seasonal influenza vaccine in July 2025. Principal supply would start on 1 December 2027 for the various vaccines, and on 1 April 2027 for the Influenza vaccine.
The approximate gross annual expenditure varies by vaccine. Usage data of currently funded vaccines has been provided as a separate attachment (Appendix 1).
For current funding restrictions please view the Pharmaceutical Schedule (https://schedule.pharmac.govt.nz/ScheduleOnline.php?code=A45). Pharmac would also be interested in considering offers for vaccines that use technologies not currently used in vaccines that are funded in New Zealand.
As part of this potential RFP, Pharmac may consider changes to funding eligibility criteria. Please refer to the Pharmac application tracker for consideration of funding applications we have had for widened access for various vaccines (https://connect.pharmac.govt.nz/apptracker/s/).
The suggested approach for suppliers would be to make any funding applications for potential new vaccines for currently funded populations, or changes to the indications for existing vaccines as soon as possible (no later than 30 April 2025). For the purposes of the Vaccines RFP process and recognising the long lead times required for vaccine manufacture and supply, the Immunisation Advisory Committee may consider vaccines or indications that have been submitted to Medsafe for assessment, prior to Medsafe approval, in order to support the procurement timelines. Information on Pharmac’s parallel assessment pathway is available on the Pharmac website (https://www.pharmac.govt.nz/news-and-resources/news/2024-02-28-media-release-parallel-assessment).
The next Immunisation Advisory Committee meeting is scheduled for June 2025. Applications for consideration at this meeting should be submitted no later than 30 April 2025.
